The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Highlights from IMS 2024: key clinical trials presented
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his highlights from the 2024 International Myeloma Society (IMS) meeting, outlining some key clinical trials presented at the conference. These include the MIDAS trial (NCT04934475), the AURIGA trial (NCT03901963), and the CEPHEUS trial (NCT03652064). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
